Elusys Therapeutics Revenue, Growth & Competitor Profile

DBA ELUSYS

Company Profile & Annual Report for Elusys Therapeutics

Access the complete profile.

Elusys Therapeutics Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	5417 Scientific Research & Development Services
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing 541711 Research & Development in Biotechnology
Address	2001 Route 46 Ste 310 Parsippany, NJ 07054

Note: Revenues for privately held companies are statistical evaluations.


Elusys Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Elusys Therapeutics's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Elusys Therapeutics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Elusys Therapeutics Annual Revenue and Growth Rate

Elusys Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Elusys Therapeutics's revenues are gauged from an analysis of company filings.

Elusys Therapeutics's Income Statement (based on Industry Averages)

Elusys Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Elusys Therapeutics is developing and marketing. Elusys Therapeutics doesn't have any recent trademark applications, indicating Elusys Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
ANTHIM PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ANTHRAX INFECTION	05/12/2006
ELUSYS pharmaceutical and drug preparations for the treatment of infectious diseases, toxins, [ autoimmune diseases, cancer, drug overdoses and tumor necrosis factor, ] excluding diagnostic agents and reagents for clinical and/or medical use	10/19/1999

See all trademarks and details in the Full Report.

Market Share of Elusys Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Elusys Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Elusys Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
SOLVIAS	Fort Lee, NJ	100
HISENSE PHOTONICS	South Plainfield, NJ	46
PACIRA THERAPEUTICS	Parsippany, NJ	35
PANDION THERAPEUTICS	Rahway, NJ	25
ELEVAR THERAPEUTICS	Fort Lee, NJ	21
MAXENTRIC TECHNOLOGIES	Fort Lee Borough, NJ	16

Future Competition: Elusys Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Elusys Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)